Tissue of Origin determination

Definitive Diagnostics develops an AI-enabled, protein-based blood test platform for earlier cancer detection. Its patented method measures 16 abundant protein/immune biomarkers forming cancer-specific patterns, designed to reduce false positives and unnecessary procedures. The company reports independent validation of 99% sensitivity (Stage 0 breast), 97% specificity, and 98% Tissue of Origin, and has detected cancer as early as Stage 0 in breast and Stage I in lung, colorectal, ovarian, and pancreatic cancers.

Read more

AI-supported detectionbiomarker measurementliquid biopsyprotein pattern recognition